OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Net Cash Provided by Financing Activities

Last Annual Value

12.78M

3-Year CAGR

61%

5-Year CAGR

-67%

10-Year CAGR

-43%

OT

OS Therapies Incorporated Competitors Analysis of Net Cash Provided by Financing Activities

OSTX · NYSE
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
12.78M
64.4%33.2%N/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
46.40M
60.9%6.9%38.2%
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
244.02K
N/A-58.9%-30.0%
101.64M
4.8%5.3%N/A
26.29M
30.4%6.5%5.8%
9.71M
36.0%141.0%N/A
6.03M
-53.1%-44.0%N/A
43.48M
-4.0%132.3%N/A
13.74M
40.9%10.8%N/A
23.28M
55.4%-18.2%N/A
44984.98B
9621.1%1415.9%302.9%
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42